marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-13-2024
DiaMedica Therapeutics Balance Sheet 2011-2024 | DMAC
Annual Balance Sheet DiaMedica Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.46 M | -4.66 M | -4.7 M | -7.23 M | -3.7 M | -16.8 M | -1.35 M | -1.74 M | -166 K | -204 K | -2.52 M | -2.34 M | -2.65 M |
Long Term Debt |
1 K | 4 K | 3 K | 7 K | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
80 K | 63 K | 4 K | 59 K | 54 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
317 K | 400 K | 3 K | 53 K | 118 K | 18 K | - | - | 388 K | - | - | - | - |
Total Current Liabilities |
2.79 M | 2.17 M | 1.52 M | 2.03 M | 1.32 M | 1.3 M | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | 2.08 M | 1.44 M | 1.31 M | 1 M | 627 K | 1.45 M | 1.81 M | 1.52 M | 1.58 M | 365 K |
Deferred Revenue |
- | - | - | - | - | - | - | - | 33 K | - | - | - | - |
Retained Earnings |
-116 M | -96.2 M | -82.5 M | -68.9 M | -56.6 M | -46 M | -40.2 M | -46.7 M | -34 M | -38.9 M | -37.1 M | -31.8 M | -21.2 M |
Total Assets |
54.2 M | 34.4 M | 45.6 M | 28.1 M | 9.05 M | 18.3 M | 1.8 M | 1.87 M | 222 K | 282 K | 2.91 M | 3.85 M | 6.33 M |
Cash and Cash Equivalents |
4.54 M | 4.73 M | 4.71 M | 7.41 M | 3.88 M | 16.8 M | - | - | - | - | - | - | - |
Book Value |
54.2 M | 34.4 M | 45.6 M | 26 M | 7.62 M | 17 M | 799 K | 1.25 M | -1.23 M | -1.53 M | 1.38 M | 2.26 M | 5.96 M |
Total Shareholders Equity |
51.1 M | 31.8 M | 44 M | 26 M | 7.62 M | 17 M | 799 K | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet DiaMedica Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
14 K | 16 K | - | 1 K | 3 K | 357 K | 377 K | 4 K | 5 K | 7 K | 9 K | 3 K | 4 K | 5 K | 5 K | 7 K | 7 K | 7 K | 7 K | 13 K | 13 K | 13 K | 13 K | 18 K | 18 K | 18 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
263 K | 288 K | 294 K | 317 K | 340 K | 361 K | 381 K | 400 K | 420 K | 7 K | 9 K | 3 K | 4 K | 16 K | 33 K | 53 K | 53 K | 53 K | 53 K | 118 K | 118 K | 118 K | 118 K | 18 K | 18 K | 18 K | 18 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-132 M | -126 M | -121 M | -116 M | -110 M | -106 M | -101 M | -96.2 M | -92.4 M | -89.4 M | -86 M | -82.5 M | -79.3 M | -75.8 M | -72.5 M | -68.9 M | -68.9 M | -68.9 M | -68.9 M | -56.6 M | -56.6 M | -56.6 M | -56.6 M | -46 M | -46 M | -46 M | -46 M | -40.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
52.5 M | 56.8 M | 49.3 M | 54.2 M | 58.1 M | 62 M | 30.2 M | 34.4 M | 37 M | 39.3 M | 42.2 M | 45.6 M | 48.7 M | 21.8 M | 24.4 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 9.05 M | 9.05 M | 9.05 M | 9.05 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
4.13 M | 14.1 M | 2.1 M | 4.54 M | 2.23 M | 5.84 M | 2.15 M | 4.73 M | 2.77 M | 3.06 M | 3.03 M | 4.71 M | 16.2 M | 2.23 M | 3.33 M | 7.41 M | 7.41 M | 7.41 M | 7.41 M | 3.88 M | 3.88 M | 3.88 M | 3.88 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 1.35 M | - | - | - | 1.74 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
52.5 M | 56.8 M | 49.3 M | 54.2 M | 58.1 M | 62 M | 30.2 M | 34.4 M | 37 M | 39.3 M | 42.2 M | 45.6 M | 48.7 M | 21.8 M | 24.4 M | 28.1 M | 28.1 M | 28.1 M | 28.1 M | 9.05 M | 9.05 M | 9.05 M | 9.05 M | 18.3 M | 18.3 M | 18.3 M | 18.3 M | 1.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
48 M | 53.4 M | 46.3 M | 51.1 M | 55.6 M | 59.7 M | 27 M | 31.8 M | 35.1 M | 37.7 M | 40.8 M | 44 M | 47 M | 20.3 M | 23.1 M | 26 M | 26 M | 26 M | 26 M | 7.62 M | 7.62 M | 7.62 M | 7.62 M | 17 M | 17 M | 17 M | 17 M | 799 K | - | - | - | 1.11 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency